And as mentioned at the BIOX conference, by another immunotherapy company, a large factor to investment interest is when big pharma starts poking around.
paraphrased: Big pharma typically won't come in until there is phase 2 data.
Some may think interim data is enough...
So, Phase 2 is when the larger investors start climbing on board.
Where are we again?
Not many stops between now and then.
have my doubts, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.0¢ | 31.0¢ | $378.4K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 378079 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 53404 | 10 |
View Market Depth
| Last trade - 12.31pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |